Immune profiling of age and adjuvant-specific activation of human blood mononuclear cells in vitro

Simone S. Schüller,Soumik Barman,Raul Mendez-Giraldez,Dheeraj Soni,John Daley,Lindsey R. Baden,Ofer Levy,David J. Dowling

DOI: https://doi.org/10.1038/s42003-024-06390-4

IF: 6.548

2024-06-09

Communications Biology

Abstract:Vaccination reduces morbidity and mortality due to infections, but efficacy may be limited due to distinct immunogenicity at the extremes of age. This raises the possibility of employing adjuvants to enhance immunogenicity and protection. Early IFNγ production is a hallmark of effective vaccine immunogenicity in adults serving as a biomarker that may predict effective adjuvanticity. We utilized mass cytometry (CyTOF) to dissect the source of adjuvant-induced cytokine production in human blood mononuclear cells (BMCs) from newborns (~39-week-gestation), adults (~18-63 years old) and elders (>65 years of age) after stimulation with pattern recognition receptors agonist (PRRa) adjuvants. Dimensionality reduction analysis of CyTOF data mapped the BMC compartment, elucidated age-specific immune responses and profiled PRR-mediated activation of monocytes and DCs upon adjuvant stimulation. Furthermore, we demonstrated PRRa adjuvants mediated innate IFNγ induction and mapped NK cells as the key source of TLR7/8 agonist (TLR7/8a) specific innate IFNγ responses. Hierarchical clustering analysis revealed age and TLR7/8a-specific accumulation of innate IFNγ producing γδ T cells. Our study demonstrates the application of mass cytometry and cutting-edge computational approaches to characterize immune responses across immunologically distinct age groups and may inform identification of the bespoke adjuvantation systems tailored to enhance immunity in distinct vulnerable populations.

biology

What problem does this paper attempt to address?

The paper attempts to address the issue of how pattern recognition receptor agonists (PRRa) as vaccine adjuvants affect the immune activation characteristics of human blood mononuclear cells (BMCs) across different age groups (newborns, adults, and the elderly). Specifically, the study aims to:

1. **Evaluate the immune activation effect of PRRa as vaccine adjuvants across different age groups**: By analyzing the cellular composition of BMCs and the sources of innate cytokine production, particularly interferons (IFNs), which are crucial for host defense and vaccine response.

2. **Reveal age-specific immune responses**: Using high-dimensional mass cytometry (CyTOF) and machine learning algorithms (such as tSNE-CUDA and SPADE), the study investigates the differences in immune cell profiles across different age groups, providing a basis for developing age-specific vaccine adjuvants.

3. **Identify key innate immune cells**: By stimulating BMCs and analyzing cytokine production, the study aims to determine which cells (such as natural killer NK cells and γδT cells) respond most significantly to PRRa in different age groups.

4. **Optimize the selection of vaccine adjuvants**: By comparing the effects of different PRRa (such as Alum, MPLA, R848, and CpG), the study seeks to identify which adjuvant can most effectively induce innate immune responses, particularly the production of IFN γ, in different age groups.

Overall, the goal of this research is to provide scientific evidence for the development of more effective age-specific vaccine adjuvants through a detailed analysis of immune responses across different age groups.